Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
June 2019
-
Key ReleaseNovartis announces new leader of Pharmaceuticals Business UnitMarie-France Tschudin, an experienced Novartis leader, appointed to President, Novartis Pharmaceuticals Basel, June 7, 2019 - Novartis announced today that Marie-France Tschudin, currently…
-
Key ReleaseNovartis stellt neue Leiterin der Pharmaceuticals Business Unit vorMarie-France Tschudin, erfahrene Novartis Führungsperson, zur Präsidentin von Novartis Pharmaceuticals ernannt Basel, 7. Juni 2019 - Novartis kündigte heute an, dass Marie-France Tschudin,…
-
Media ReleaseAdvanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare®Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium (177Lu)…
-
Media ReleaseNovartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possibleData show 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus (current standard of care)[1] Less than half of donated…
-
Media ReleaseLong-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine…
-
Toward improving the health and longevity of transplanted organs
Novartis researchers are working to extend the life of organ transplants
-
Media ReleaseNovartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical TrialsPrimary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (…
-
Media ReleaseXolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studiesIn the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate…
-
Media ReleaseNovartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trialKisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1] After a median of 42 months follow-up, the survival rate was 70.2% for…
May 2019
-
Media ReleaseNovartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthmaLow dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to…
-
Women in Science: Shannon Campbell
How Shannon Campbell, Senior Vice President & Franchise Head at Novartis Oncology, came into her current role and leadership position.
-
Investigating the myopia mystery
Two scientists from Basel are trying to shed light on why myopia is impacting more and more people.
Pagination
- ‹ Previous page
- 1
- …
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- …
- 152
- › Next page